COVID-19 disease. COVID-19, virus not identified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age >20 years Positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging Primary clinical symptoms Hospitalized and moderate patients Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm
Exclusion criteria
Exclusion criteria: Patients with underlying diseases including hypertension, diabetes, seizure, depression, chronic hepatitis, cirrhosis, and cholestatic liver diseases Use of anticoagulant drugs like warfarin, hormonal drugs, alcohol, and any illegal drugs (during last 30 days) History of allergy to Melatonin Pregnancy and breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: Respiratory Count.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymphocytopenia. Timepoint: Before intervention and 7 days after the start of the intervention. Method of measurement: Cell count.;C-reactive protein. Timepoint: Before intervention and 7 days after the start of the intervention. Method of measurement: C-RP kit.;Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Bandare-abbas University of Medical Sciences